Clement Hamani1, Julie Pilitsis, Anand I Rughani, Joshua M Rosenow, Parag G Patil, Konstantin S Slavin, Aviva Abosch, Emad Eskandar, Laura S Mitchell, Steven Kalkanis. 1. *Division of Neurosurgery, Toronto Western Hospital, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; ‡Department of Neurosurgery and Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York; §Neuroscience Institute, Maine Medical Center, Portland, Maine; ¶Department of Neurosurgery, Northwestern University, Chicago, Illinois; ‖Departments of Neurosurgery, Neurology, Anesthesiology, and Biomedical Engineering, University of Michigan, Ann Arbor, Michigan; #Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois; **Department of Neurosurgery, University of Colorado, Denver, Colorado; ‡‡Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts; §§Congress of Neurological Surgeons, Guidelines Department, Schaumburg, Illinois; ¶¶Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan.
Abstract
BACKGROUND: It is estimated that 40% to 60% of patients with obsessive-compulsive disorder (OCD) continue to experience symptoms despite adequate medical management. For this population of treatment-refractory patients, promising results have been reported with the use of deep brain stimulation (DBS). OBJECTIVE: To conduct a systematic review of the literature and develop evidence-based guidelines on DBS for OCD. METHODS: A systematic literature search was undertaken using the PubMed database for articles published between 1966 and October 2012 combining the following words: "deep brain stimulation and obsessive-compulsive disorder" or "electrical stimulation and obsessive-compulsive disorder." Of 353 articles, 7 were retrieved for full-text review and analysis. The quality of the articles was assigned to each study and the strength of recommendation graded according to the guidelines development methodology of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Joint Guidelines Committee. RESULTS: Of the 7 studies, 1 class I and 2 class II double-blind, randomized, controlled trials reported that bilateral DBS is more effective in improving OCD symptoms than sham treatment. CONCLUSION: Based on the data published in the literature, the following recommendations can be made: (1) There is Level I evidence, based on a single class I study, for the use of bilateral subthalamic nucleus DBS for the treatment of medically refractory OCD. (2) There is Level II evidence, based on a single class II study, for the use of bilateral nucleus accumbens DBS for the treatment of medically refractory OCD. (3) There is insufficient evidence to make a recommendation for the use of unilateral DBS for the treatment of medically refractory OCD.
BACKGROUND: It is estimated that 40% to 60% of patients with obsessive-compulsive disorder (OCD) continue to experience symptoms despite adequate medical management. For this population of treatment-refractory patients, promising results have been reported with the use of deep brain stimulation (DBS). OBJECTIVE: To conduct a systematic review of the literature and develop evidence-based guidelines on DBS for OCD. METHODS: A systematic literature search was undertaken using the PubMed database for articles published between 1966 and October 2012 combining the following words: "deep brain stimulation and obsessive-compulsive disorder" or "electrical stimulation and obsessive-compulsive disorder." Of 353 articles, 7 were retrieved for full-text review and analysis. The quality of the articles was assigned to each study and the strength of recommendation graded according to the guidelines development methodology of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Joint Guidelines Committee. RESULTS: Of the 7 studies, 1 class I and 2 class II double-blind, randomized, controlled trials reported that bilateral DBS is more effective in improving OCD symptoms than sham treatment. CONCLUSION: Based on the data published in the literature, the following recommendations can be made: (1) There is Level I evidence, based on a single class I study, for the use of bilateral subthalamic nucleus DBS for the treatment of medically refractory OCD. (2) There is Level II evidence, based on a single class II study, for the use of bilateral nucleus accumbens DBS for the treatment of medically refractory OCD. (3) There is insufficient evidence to make a recommendation for the use of unilateral DBS for the treatment of medically refractory OCD.
Authors: Carrie L Wade; Marsida Kallupi; Daniel O Hernandez; Emmanuel Breysse; Giordano de Guglielmo; Elena Crawford; George F Koob; Paul Schweitzer; Christelle Baunez; Olivier George Journal: Neuropsychopharmacology Date: 2016-12-05 Impact factor: 7.853
Authors: Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson Journal: Nat Rev Dis Primers Date: 2019-08-01 Impact factor: 52.329
Authors: Kala Venkiteswaran; Danielle N Alexander; Matthew D Puhl; Anand Rao; Amanda L Piquet; Jennifer E Nyland; Megha P Subramanian; Puja Iyer; Matthew M Boisvert; Erin Handly; Thyagarajan Subramanian; Patricia Sue Grigson Journal: Brain Res Bull Date: 2015-11-10 Impact factor: 4.077
Authors: Nataly Raviv; Michael D Staudt; Andrew K Rock; Jacquelyn MacDonell; Julia Slyer; Julie G Pilitsis Journal: Neurosurgery Date: 2020-11-16 Impact factor: 4.654
Authors: Michael D Staudt; Nader Pouratian; Jonathan P Miller; Clement Hamani; Nataly Raviv; Guy M McKhann; Jorge A Gonzalez-Martinez; Julie G Pilitsis Journal: Neurosurgery Date: 2021-03-15 Impact factor: 4.654